Skip to main content
SpringerLink
Log in

Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The distribution and biologic activity of somatostatin receptor subtypes (SSTR) in pituitary adenomas is not clarified, especially regarding clinically non-functioning adenomas (NFPA). We therefore characterized SSTR in human pituitary adenomas by combining molecular biology and in vivo scintigraphy. Co-expression of gonadotropin-re-leasing hormone receptor (GnRH-R) mRNA was also assessed to see whether this feature was associated with adenoma subtype and SSTR status. Pituitary tumor biopsies were obtained during transsphenoidal adenomectomy from 21 patients (11 NFPA, 7 acromegalics, 2 prolactinomas, 1 Cushing’s disease). Expression of mRNA encoding the 5 known SSTR subtypes and the GnRH-R was determined by RT-PCR. Twelve patients also underwent a pre-operative somatostatin receptor scintigraphy. Most adenomas (no.=18) expressed mRNA for more than one SSTR. SSTR2 mRNA was expressed in 18 cases, whereas SSTR4 was absent in all but one. SSTR3 was frequently expressed in NFPAs. Somatostatin receptor scintigraphy was positive in most cases, and with a significantly higher uptake index in GH-producing adenomas all of which expressed SSTR2 mRNA. The uptake index appeared to be related to receptor density rather than tumor volume. Expression of GnRH-R mRNA was found in both NFPAs and GH-producing adenomas and was not significantly associated with a particular SSTR subtype population. In conclusion: 1) the distribution of SSTR is not significantly different between NFPA and GH-producing adenomas; and 2) somatostatin receptor scintigraphy reveals a higher uptake in GH-producing adenomas which is not significantly related to either SSTR distribution or tumor volume.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Katznelson L., Oppenheim D.S., Coughlin J.F., Kliman B., Schoenfeld D.A., Klibanski A. Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors. J. Clin. Endocrinol. Metab. 1992, 75: 1318–1325.

    CAS  PubMed  Google Scholar 

  2. Broson Chazot F., Houzard C., Ajzenberg C., Nocaudie M., Duet M., Mundler O., Marchandise X., Epelbaum J., Gomez De Alzaga M., Schafer J., Meyerhof W., Sassolas G., Warnet A. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. Clin. Endocrinol. Oxf. 1997, 47: 589–598.

    Article  CAS  PubMed  Google Scholar 

  3. Kubota A., Yamada Y., Kagimoto S., Shimatsu A., Imamura M., Tsuda K., Imura H., Seino S., Seino Y. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201–995 in treatment of human endocrine tumors. J. Clin. Invest. 1994, 93: 1321–1325.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Plockinger U., Reichel M., Fett U., Saeger W., Quabbe H.J. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J. Clin. Endocrinol. Metab. 1994, 79: 1416–1423.

    CAS  PubMed  Google Scholar 

  5. Rieger A., Rainov N.G., Elfrich C., Klaua M., Meyer H., Lautenschlager C., Burkert W., Mende T. Somatostatin receptor scintigraphy in patients with pituitary adenoma Somatostatin receptor scintigra-phy in patients with pituitary adenoma. Neurosurg. Rev. 1997, 20: 7–12.

    Article  CAS  PubMed  Google Scholar 

  6. Shimon I., Taylor J.E., Dong J.Z., Bitonte R.A., Kim S., Morgan B., Coy D.H., Culler M.D., Melmed S. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J. Clin. Invest. 1997, 99: 789–798.

    Google Scholar 

  7. Greenman Y., Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J. Clin. Endocrinol. Metab. 1994, 78: 398–403.

    CAS  PubMed  Google Scholar 

  8. Greenman Y., Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J. Clin. Endocrinol. Metab. 1994, 79: 724–729.

    CAS  PubMed  Google Scholar 

  9. Miller G.M., Alexander J.M., Bikkal H.A., Katznelson L., Zervas N.T., Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 1995, 80: 1386–1392.

    CAS  PubMed  Google Scholar 

  10. Panetta R., Patel Y.C. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci. 1995, 56: 333–342.

    Article  CAS  PubMed  Google Scholar 

  11. Florio T., Thellung S., Arena S., Corsaro A., Spaziante R., Gussoni G., Acuto G., Giusti M., Giordano G., Schettini G. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur. J. Endocrinol. 1999, 141: 396–408.

    Article  CAS  PubMed  Google Scholar 

  12. Jaquet P., Ouafik L., Saveanu A., Gunz G., Fina F., Dufour H., Culler M.D., Moreau J.P., Enjalbert A. Quantitative and functional expression of somato-statin receptor subtypes in human prolactinomas. J. Clin. Endocrinol. Metab. 1999, 84: 3268–3276.

    CAS  PubMed  Google Scholar 

  13. Jaquet P., Saveanu A., Gunz G., Fina F., Zamora A.J., Grino M., Culler M.D., Moreau J.P., Enjalbert A., Ouafik L.H. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J. Clin. Endocrinol. Metab. 2000, 85: 781–792.

    CAS  PubMed  Google Scholar 

  14. Kovacs K., Scheithauer B.W., Horvath E., Lloyd R.V. The World Health Organization classification of adeno-hypophysial neoplasms. A proposed five-tier scheme. Cancer 1996, 78: 502–510.

    Article  CAS  PubMed  Google Scholar 

  15. Snyder P.J. Extensive personal experience: gonadotroph adenomas. J. Clin. Endocrinol. Metab. 1995, 80: 1059–1061.

    CAS  PubMed  Google Scholar 

  16. Alexander J.M., Klibanski A. Gonadotropin-releasing hormone receptor mRNA expression by human pituitary tumors in vitro. J. Clin. Invest. 1994, 93: 2332–2339.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. de Bruin T.W., Kwekkeboom D.J., Van’t Verlaat J.W., Reubi J.C., Krenning E.P., Lamberts S.W., Croughs R.J. Clinically nonfunctioning pituitary adenoma and oc-treotide response to long term high dose treatment, and studies in vitro. J. Clin. Endocrinol. Metab. 1992, 75: 1310–1317.

    PubMed  Google Scholar 

  18. Krenning E.P., Kwekkeboom D.J., Bakker W.H., Breeman W.A., Kooij P.P., Oei H.Y., van Hagen M., Postema P.T., de Jong M., Reubi J.C., Lamberts S.W. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993, 20: 716–731.

    Article  CAS  PubMed  Google Scholar 

  19. Duet M., Mundler O., Ajzenberg C., Berolatti B., Chedin P., Duranteau L., Warnet A. Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index. Eur. J. Nucl. Med. 1994, 21: 647–650.

    Article  CAS  PubMed  Google Scholar 

  20. Maini C.L., Sciuto R., Tofani A., Ferraironi A., Carapella C.M., Occhipinti E., Mottolese M., Crecco M. Somatostatin receptor imaging in CNS tumours using 111In-octreotide. Nucl. Med. Commun. 1995, 16: 756–766.

    Article  CAS  PubMed  Google Scholar 

  21. Heitz P.U., Landolt A.M., Zenklusen H.R., Kasper M., Reubi J.C., Oberholzer M., Roth J. Immunocytochemistry of pituitary tumors. J. Histochem. Cytochem. 1987, 35: 1005–1011.

    Article  CAS  PubMed  Google Scholar 

  22. Reubi J.C., Heitz P.U., Landolt A.M. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J. Clin. Endocrinol. Metab. 1987, 65: 65–73.

    Article  CAS  PubMed  Google Scholar 

  23. Hofland L.J., Lamberts S.W. Somatostatin receptors and disease: role of receptor subtypes. Baillieres Clin. Endocrinol. Metab. 1996, 10: 163–176.

    Article  CAS  PubMed  Google Scholar 

  24. Plockinger U., Bader M., Hopfenmuller W., Saeger W., Quabbe H.J. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to octreotide therapy and do not correlate with tumor histology. Eur. J. Endocrinol. 1997, 136: 369–376.

    Article  CAS  PubMed  Google Scholar 

  25. Duet M., Ajzenberg C., Benelhadj S., Lajeunie E., Lormeau B., Guillausseau P.J., Rohmer V., Vilain D., Mundler O., Warnet A. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo. J. Nucl. Med. 1999, 40: 1252–1256.

    CAS  PubMed  Google Scholar 

  26. Miller G.M., Alexander J.M., Klibanski A. Gonadotropin-releasing hormone messenger RNA expression in gonadotroph tumors and normal human pituitary. J. Clin. Endocrinol. Metab. 1996, 81: 80–83.

    CAS  PubMed  Google Scholar 

  27. Sanno N., Jin L., Qian X., Osamura R.Y., Scheithauer B.W., Kovacs K., Lloyd R.V. Gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor messenger ribonucleic acids expression in nontumorous and neoplastic pituitaries. J. Clin. Endocrinol. Metab. 1997, 82: 1974–1982.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department M (Diabetes and Endocrinology), Aarhus Kommunehospital, Aarhus University Hospital, DK-8000, Aarhus C, Denmark

    Steen Nielsen, S. Mellemkjær, J. Weeke & J. O. L. Jørgensen

  2. Laboratory for Molecular Pathology, Aarhus Kommunehospital, Aarhus University Hospital, Aarhus, Denmark

    L. M. Rasmussen

  3. Research Laboratory for Biochemical Pathology, Aarhus Kommunehospital, Aarhus University Hospital, Aarhus, Denmark

    T. Ledet

  4. Department of Nuclear Medicine, Aarhus Kommunehospital, Aarhus University Hospital, Aarhus, Denmark

    N. Olsen

  5. Department of Neuropathology, Aarhus Kommunehospital, Aarhus University Hospital, Aarhus, Denmark

    M. Bojsen-Møller

  6. Department of Neurosurgery, Aarhus Kommunehospital, Aarhus University Hospital, Aarhus, Denmark

    J. Astrup

Authors
  1. Steen Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Mellemkjær
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. M. Rasmussen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Ledet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Olsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Bojsen-Møller
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Astrup
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Weeke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. O. L. Jørgensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steen Nielsen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nielsen, S., Mellemkjær, S., Rasmussen, L.M. et al. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo . J Endocrinol Invest 24, 430–437 (2001). https://doi.org/10.1007/BF03351043

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03351043

Key-words

Search

Navigation